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Summary We report a 49-year-old female patient with recurrent large left ventricular throm-
bus on echocardiogram in an apparently normal heart and insigniﬁcant cardiac past medical
history. She underwent an excision of the left ventricular mass, ﬁnal biopsy on which proved it
to be a thrombus. Postoperative anti-coagulation was initiated with enoxaparin and warfarin
and the patient was followed up at a cardiology clinic 6 weeks later. A repeat trans-thoracic
echocardiogram revealed a new mass arising from the left atrium. Considering the increased
risk of repeat ventriculostomy, she was treated conservatively with her current management.
During this time the patient’s pro-thrombotic work-up revealed positive prothrombin G20210
mutation. A follow up trans-thoracic echocardiogram done 2 months later surprisingly revealed
complete resolution of the intracardiac mass. Our patient had prothrombin G20210 mutation, an
entity primarily known for deep venous thrombosis, which rarely causes intra-arterial throm-
bus, intra-cardiac being unreported. There are no established protocols for management of
these cases. The rate of embolic episodes in mobile pedunculated thrombi is reported as high
as 60%. Patients with prior embolism must be offered immediate surgery, especially if the
thrombus is large with an irregular surface, pedunculated, and multiple in number. Aggressive
anti-coagulation with close monitoring is essential.
Published by Elsevier Ltd. All rights reserved.
e1. Case reportWe present a case of a 49-year-old Hispanic female who pre-
sented to the emergency room with shortness of breath on
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doi:10.1016/j.jccase.2011.02.002xertion, which had been ongoing for one month. Her past
edical history was signiﬁcant for anxiety and hypertension
or 5 years for which she was on metoprolol. She denied
aking any other medications. The patient had a history of
ysterectomy. She denied smoking, alcohol abuse, or recre-
tional drug abuse. There was no signiﬁcant family history
or medical illness.She was afebrile on examination, pulse rate was 72 beats
er minute, respiratory rate was 16 breaths per minute and
lood pressure was 132/82mmHg. No signs of endocarditis
ere noted on general exam.
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pig. 1 Trans-esophageal echocardiogram showing a partly
edunculated thrombus in the left ventricle.
Heart auscultation did not reveal murmurs, rubs, or gal-
lops.
Chest was clear to auscultation bilaterally.
Her complete blood count was essentially normal with a
platelet count of 236,000 per mm3. Her prothrombin time
was 11 s and international normalized ratio (INR) was 1.
Her C-reactive protein was 13mg/L. Autoimmune panel
was negative. Antithrombin was 24.6mg/dL, and anti-
cardiolipin, IgG, and IgM were negative. Homocysteine was
6.8mol/L, factor V Leiden was negative.
Patient protein C was 11 IU/dL and protein S 20 IU/dL.
On initial work-up she was found to have a left ventricular
mass on echocardiogram.
A trans-esophageal echocardiogram conﬁrmed this (Fig. 1).
The patient did not have clinical signs suggestive of vascu-
lar thrombosis in other organ system.
She was afebrile and blood cultures were negative. Cardio-
thoracic surgery was consulted. She had an excision of the
left ventricular mass and recovered from this well post-
operatively. Intra-operative ﬁndings speciﬁed a large left
ventricular mass afﬁxed to the base of the left posterolat-
eral papillary muscle at two discrete locations. Final biopsy
demonstrated a thrombus (Fig. 2).
ig. 2 A Hematoxylin & Eosin stained slide of the excised
ardiac thrombus showing characteristic clumps of platelets
nterspersed with thrombin.
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aig. 3 Trans-thoracic view of a new pedunculated thrombus
n the atrium.
Anticoagulation was initiated with enoxaparin and war-
arin for ﬁrst few days and later switched to warfarin only.
he had been therapeutic on warfarin for the last couple of
ays before discharge in a stable condition.
At routine follow-up at 6 weeks, the patient had no unto-
ard symptoms and the patient’s INR was therapeutic. A
epeat trans-thoracic echocardiogram was ordered which
evealed a new mass arising from the left atrium (Fig. 3).
his study was followed-up by a trans-esophageal echocar-
iogram conﬁrming the ﬁnding (Fig. 4).
During this time period patient’s pro-thrombotic work-up
evealed positive prothrombin G20210 mutation.
A decision was made after consultation with cardio-
horacic surgeons to conservatively treat the patient with
nti-coagulation and monitor closely. This consensus was
eavily inﬂuenced by risk of repeat ventriculostomy.
A follow-up trans-thoracic echocardiogram 2 months
ater with the patient being on anti-coagulation therapy sur-
risingly revealed complete resolution of the intra-cardiac
ass (Fig. 5).. Discussion
e report a patient with a large left ventricular throm-
us in an apparently normal heart and insigniﬁcant cardiac
ig. 4 Trans-esophageal echocardiographic view of left
trium with a new pedunculated thrombus.
Recurrent intra-cardiac thrombosis—–A unique presentation of pr
Fig. 5 A trans-thoracic echocardiogram done 6 weeks later
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In conclusion, although we have always considered pro-
thrombin G20210 mutation to be associated with venousshows complete resolution of the thrombus.
past medical history. Our patient had prothrombin G20210
mutation, which rarely causes intra-arterial thrombus,
with intra-cardiac thrombus in a normal heart being even
rarer [1,2]. Our literature search found a case report of
right ventricular thrombus in a patient with right ven-
tricular arrythmogenic dysplasia with G20210 mutation
[3].
This entity is mainly known for deep venous thrombo-
sis [4,5] and accounts for a substantial number of inherited
thrombophilia cases [6,7]. The inﬂuence of prothrombin
gene mutation and other inherited genetic abnormalities on
arterial thrombosis remains controversial. A meta-analysis
of published case-control and cohort studies correlating the
factor V Leiden, prothrombin G20210A, and other genetic
abnormalities with myocardial infarction, ischemic stroke,
or peripheral vascular disease showed modest association
[8].
3. Prothrombin G20210A
Prothrombin (factor II) is the precursor of thrombin, the
end-product of the coagulation cascade. It is synthe-
sized in the liver and is post-translationally modiﬁed in
a vitamin K dependent reaction that converts ten glu-
tamic acids on prothrombin to gamma-carboxyglutamic
acid. It has a half-life of 3—5 days. The human pro-
thrombin gene spans 21 kb on chromosome 11p11-q12
and consists of 14 exons and 13 introns. A transi-
tion (guanine to adenine) at nucleotide 20210 in the
3′ untranslated region of the prothrombin gene was
shown as a risk factor for thrombosis [9]. Linkage
analysis demonstrates that the prothrombin G20210A
mutation is a functional polymorphism and it inﬂuences
both plasma prothrombin levels and risk of thrombosis
[9].
The proportion of the white population heterozygous for
the allele varies from 0.7% to 6.5%, with the highest preva-
lence rates reported in Spain [10]. Heterozygous carriers
have 30% higher plasma prothrombin levels than normal sub-
jects [9].
t
dothrombin G20210 mutation e131
. Risk of thrombosis
.1. Deep vein thrombosis
he G20210A prothrombin gene mutation has been found
ith greater frequency in patients with venous thrombosis
han controls in a number of studies from Europe, the USA,
nd Brazil [7,9—12]. In the Leiden Thrombophilia Study, the
0210 allele was found in 6.3% of consecutive unselected
atients with a ﬁrst episode of deep vein thrombosis in com-
arison to 2.3% of healthy matched controls who had the
rothrombin gene mutation [9] indicating that the 20210
llele is a relatively common risk factor for venous thrombo-
is. The study also showed the 20210 allele to be associated
ith elevated prothrombin levels.
However, data on the rate of recurrent deep vein throm-
oses remains ambiguous. Two meta-analyses have come
o differing conclusions concerning whether the presence
f the prothrombin gene mutation is (odds ratio 1.72; 95%
I 1.27-2.31) [13], or is not (odds ratio 1.4; 95% CI 0.90-
.0) [14], associated with an increased risk for deep vein
hrombosis recurrence.
The prothrombin gene mutation is also a risk factor for
erebral venous thrombosis particularly in the presence of
xposure to oral contraceptives [15].
.2. Arterial thrombosis
s mentioned earlier the association of prothrombin gene
utation and arterial thrombosis remains controversial.
lthough the prothrombin gene mutation is not a risk factor
or cerebrovascular ischemic disease in older patients [16]
relation to stroke in younger patients has been suggested.
In a study conducted by De Stefano et al. [17] 12.5%
9/72) of patients with ischemic stroke before reaching 50
ears of age and with absence of hypertension or evident
etabolic risk factors were found to be carriers of the
actor II G20210 gene mutation in contrast to 2.5% in 198
ontrols (7.6% versus 1.2%) [17]. Similarly, a study done by
alouschek et al. [18] in male patients with a documented
troke/transient ischemic attack before 60 years of age, the
revalence of the prothrombin gene mutation was signiﬁ-
antly higher than in controls (6% versus 1%). No signiﬁcance
as observed in female subjects [18].
Modest overall association was reported between the risk
or myocardial infarction and ischemic stroke, particularly
mong younger patients and women with prothrombin and
ther genetic abnormalities [8,19].
There are no established protocols for management of
hese cases. Though dissolution of cardiac thrombus with
nticoagulant therapy is reported in the literature [1], risk of
mbolization is ever lurking. The rate of embolic episodes in
obile pedunculated thrombi is reported as high as 60% [20].
atients with prior embolism must be offered immediate
urgery, especially if the thrombus is large with an irregular
urface, pedunculated, and multiple in numbers. Aggressive
nticoagulation with close monitoring is essential.hrombosis, this case establishes the importance of eluci-
ating prothrombin G20210 mutation as a cause of arterial
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ystem thrombosis. The fact that this patient had recur-
ent thrombosis in the heart, a high pressure system, shows
hat patients with this condition have a strong predilection
or thrombosis and the threshold for evaluation and treat-
ent should be low. Testing for G20210 should be strongly
onsidered in select individuals.
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